ArticleAmerican journal of translational research2026
Expression of serum inflammatory markers in colorectal cancer and their relationship with clinical pathological characteristics.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis retrospective study primarily aimed to measure serum inflammatory markers in colorectal cancer and examine their relationship with clinical pathological characteristics.
methodsA total of 147 CRC patients (assigned to the training group (103 cases) or the validation group (44 cases) at a 7:3 ratio) and 100 control participants were enrolled. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) levels in serum were compared between the training and control groups. The diagnostic value of these markers for CRC and their relationship with the clinical pathological characteristics of CRC patients were evaluated. The correlations among inflammatory markers and their correlations with tumor markers were analyzed. Finally, the clinical data of the training and validation groups were compared, and the diagnostic value of each inflammatory marker was verified in the validation group.
resultsInflammatory markers were notably elevated in the CRC group and showed significant correlations with Tumor-Node-Metastasis (TNM) staging, lymph node metastasis (LNM), and tumor diameter. Additionally, all these three markers showed positive correlations with each other and with tumor markers. Each inflammatory marker demonstrated certain diagnostic efficacy for clinical pathological characteristics. Specifically, IL-6 exhibited outstanding efficacy for LNM (area under the curve (AUC) = 0.798), and CRP performed best in differentiating tumor diameter (AUC = 0.730). Moreover, the AUC values in the validation group were comparable to those in the training group.
resultsIL-6, TNF-α, and CRP may serve as potential tools to assist in the assessment of disease progression and metastatic potential in colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.